ClinicalTrials.gg
RecruitingNCT06201455ECOUpdated Dec 11, 2024

Evaluation of Phacogoniotomy in Medically-controlled POAG

An interventional study of PEI+GT and PEI+MED in Glaucoma, Open-Angle, Cataract Complicated and Goniotomy, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Glaucoma, Open-Angle with a site in China — 7 open to participants now, 11 under way, 1 of them phase 3. Glaucoma, Open-Angle · China.

Planned enrollment
18th of 30
100 · median 120
Started
2023
with 1 other
No phase
14 of 38
2 open now
Primary completion
2026-09
later than 5 of 10 live
Registered
30th of 38
by date

Among the 38 studies in Glaucoma, Open-Angle with a site in China, this one is the 18th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 30th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 38 studies in Glaucoma, Open-Angle with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Glaucoma, Open-Angle with a site in China, or all of them as a file.
02

Study summary

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are:

  • Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG.
  • Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.
Read the detailed description

Glaucoma is the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) remaining the most common subtype.

Although there are various methods to treat POAG, medication remains the first choice. However, medication therapy has several limitations, such as multiple adverse effects, poor compliance, and high costs. Therefore, it is imperative to explore treatment modalities that reduce medication burden and improve patients' quality of life.

Minimally invasive glaucoma surgery (MIGS) has been widely employed in clinical practice in recent years and become the mainstream surgical approach for POAG treatment. Among them, various forms of Schlemm's canal-based procedures, which were commonly known as ab interno trabeculotomy or goniotomy (GT) have garnered clinical significance due to their advantages of simplicity, minimal invasiveness, low complication rates, and rapid recovery. These procedures can also be combined with phacoemulsification with intraocular lens implantation (PEI). Currently, several GT techniques have been reported using different devices with different ranges of incision. The investigators have proved that a 120-degree GT with or with PEI were effective enough to treat patients with POAG with or without cataract, providing a comparable efficacy with 240 or 360 degree GT. The 120-degree is characterized by not only its efficacy, but also its fewer complications, faster procedure and quicker recovery. Although the techniques have been implemented clinically, further research is needed to evaluate their economics value in terms of reducing patient dependence on medication, relieving the economic burden of glaucoma medications, and improving the quality of life.

Therefore, a non-inferiority randomized controlled trial (RCT) will be conducted in medically controlled POAG patients with cataract, comparing PEI+GT to PEI combined with medication therapy (PEI+MED). The trial aims to validate the effectiveness of GT in reducing medication use, lightening the burden on patients, and providing a novel treatment approach.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Cataract Complicated
  • Goniotomy

Keywords

  • Glaucoma, Open-Angle
  • Cataract
  • Goniotomy
  • Minimally invasive glaucoma surgery
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 40 ≤ Age ≤ 85 years, gender unrestricted.
  2. Diagnosed with POAG.
  3. Controlled IOP under 1 to 4 topical hypotensive medications, IOP ≤ 24 mmHg
  4. Mean deviation (MD) for perimetry ≥ -16dB.
  5. Presence of cataract and best-corrected visual acuity measured using the ETDRS chart ≤ 0.63.
  6. Voluntary participation of the patient in this study, signing an form, and agreeing to follow-up visits according to the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Any history of intraocular surgery or ocular trauma.
  2. Presence of other types of glaucoma, including primary angle-closure glaucoma and various forms of secondary glaucoma (e.g. secondary angle-closure, pigmentary, -induced, angle-recession, neovascular, inflammatory, and pseudoexfoliation syndrome).
  3. Presence of severe ocular diseases of various types that affect the acquisition of ocular parameters or interfere with perimetry.
  4. Axial length > 28 mm.
  5. Monophthalmia (best-corrected visual acuity of the non-study eye \< 0.01).
  6. Coexistence of severe systemic diseases affecting the entire body.
  7. Pregnant or lactating women.

    • If both eyes of a patient meet the criteria, the eye with worse visual acuity will be selected for inclusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PEI+GT

    Experimental group: Phacoemulsification with intraocular lens implantation (PEI) and goniotomy (GT).

    Procedure: PEI+GT

  • Active comparator
    PEI+MED

    Controll group: Phacoemulsification with intraocular lens implantation (PEI) and medication therapy (MED).

    Procedure: PEI+MED

Interventions

  • ProcedurePEI+GT

    After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).

  • ProcedurePEI+MED

    Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.

06

What researchers measure

Primary outcomes

  1. IOP at 12 months after surgery.

    The intraocular pressure (mmHg) at 12 months after surgery.

    Time frame: Postopertive 12 months.

Secondary outcomes

  1. Surgery success of surgery

    (i) Complete success (%) is defined as the postoperative 5 \< IOP ≤ 16 mmHg with no need for IOP-lowering medication, without any vision-threatening complication or need for re-operation. (ii) Qualified success (%) is defined as the postoperative 5 \< IOP ≤ 16 mmHg regardless of IOP-lowering medication, without any vision-threatening complication or need for re-operation.

    Time frame: Postoperative 3, 6, 12 months.

  2. Amount of postoperative anti-glaucomatous medications

    The amount of postoperative anti-glaucomatous medications will be measured as: types of medication (No.) × time (No.).

    Time frame: Postoperative 1, 3, 6, 12 months.

  3. Cost-effectiveness associated parameters

    Cost-effectiveness associated parameters: cost of surgery and medications; quality-adjusted life year, etc.

    Time frame: Postoperative 12 months.

Other outcomes

  1. Surgery complications

    Incidence of surgery complications.

    Time frame: Postoperative 1, 3, 6, 12 months.

  2. Visual acuity

    Unit: logMAR

    Time frame: Postoperative 1, 3, 6, 12 months.

  3. Corneal endothelial cell counting

    Unit: cells/mm\^2

    Time frame: Postoperative 12 months.

  4. Visual field

    Mean deviation (MD) and pattern standard deviation (PSD) using Humphrey perimetery

    Time frame: Postoperative 12 months.

  5. Optic nerve head morphology and retinal parameters based on optical coherence tomography

    Thickness (μm) of peripapillary retinal nerve fiber layer and macular GC-IPL are collected from optical coherence tomography device.

    Time frame: Postoperative 12 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 36 months is close to that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2023
First posted
Jan 11, 2024
StartActual
Sep 28, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2029
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06201455
Collaborators
West China Hospital, Chongqing Medical University, The Second Hospital of Anhui Medical University, Handan City Eye Hospital, Shijiazhuang People's Hospital, Chengdu First People's Hospital, Guangdong Hospital of Traditional Chinese Medicine, Zhuhai, Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Huizhou Municipal Central Hospital
Responsible party
Xiulan Zhang (Principal Investigator, Zhongshan Ophthalmic Center, Sun Yat-sen University) — Principal investigator
First posted
Jan 11, 2024
Start date
Sep 28, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Dec 11, 2024

Study contacts

Xiulan Zhang, MD. PhD
Contact
zhangxl2@mail.sysu.edu.cn
+86 13570166308
Yunhe Song, MD, PhD
Contact
songyh33@mail.sysu.edu.cn
+86 13059106657

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion